Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-04), Aelis Farma's 14-Day RSI is 45.83.
The industry rank for Aelis Farma's 14-Day RSI or its related term are showing as below:
FRA:69O's 14-Day RSI is ranked worse than 53.73% of 1422
companies
in the Biotechnology industry
Industry Median: 44.07
vs FRA:69O: 45.83
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Aelis Farma 14-Day RSI Related Terms
FRA:69O vs VRTX, REGN, RVMD: 14-Day RSI Comparison
For the Biotechnology subindustry, Aelis Farma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aelis Farma 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aelis Farma's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Aelis Farma's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aelis Farma (FRA:69O) has a 14-Day RSI of 45.83 as of Aug. 04, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Aelis Farma and its competitors. According to the industry distribution chart, Aelis Farma ranks #764 out of 1422 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Aelis Farma's 14-Day RSI too high?
Aelis Farma's current 14-Day RSI is 45.83. The Biotechnology industry median 14-Day RSI is 44.07. Aelis Farma's value of 45.83 is 4% above this industry median. Based on the distribution chart, Aelis Farma ranks #764 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aelis Farma has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Aelis Farma's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aelis Farma ranks #764 out of 1422 companies for 14-Day RSI. This places Aelis Farma in the lower half of its industry. The industry median 14-Day RSI is 44.07. Aelis Farma's value of 45.83 is 4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 44.07, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aelis Farma's current 14-Day RSI of 45.83 is 4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Aelis Farma and its competitors. For the Biotechnology industry, the median 14-Day RSI is 44.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aelis Farma's current 14-Day RSI is 45.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aelis Farma stock overvalued right now?
Aelis Farma (FRA:69O) has a current 14-Day RSI of 45.83. The stock's GF Value™ is €0.94, compared to a current price of €0.99 — trading 5.1% above its estimated fair value. The current 14-Day RSI is 45.83 and 4% above the Biotechnology industry median of 44.07. Aelis Farma's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Aelis Farma (FRA:69O), the current 14-Day RSI is 45.83 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aelis Farma (FRA:69O) Overvalued in 2026?
Based on GuruFocus' analysis, Aelis Farma stock appears to be overvalued.
The current stock price of €0.99 is trading 5.1% above its estimated GF Value™ of €0.94.
Key valuation signals for FRA:69O:
14-Day RSI: 45.83
GF Value™: €0.94 vs. price of €0.99 (5.1% above fair value)
Industry Position: 4% above the Biotechnology median (#764 of 1422)
No single metric tells the full story. See the FRA:69O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases. The Company operates in only one business segment: the research and development of pharmaceutical products.
27GF Score
Get the complete analysis for FRA:69O
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:69O has been successfully added to your 
